As reported by Francys Romero, the Yankees have officially put pen to paper with 16-year-old Dominican shortstop Manny Cedeño, the No. 11 prospect in the 2025 international class. The potential ...

PARIS -- The desire to play with Victor Wembanyama may someday draw fellow stars to the San Antonio Spurs, but he's already attracting the next generation. That was the message Saturday from A.J ...

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) is pleased to host an upcoming webinar for financial professionals ...

Drug is the first and only approved monotherapy for refractory major depressive disorder. (HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

Parkside Psychiatric Hospital in Tulsa has an on-site Spravato outpatient clinic that sees over 20 patients per week. According to Parkside, these patients are seen at least twice a week for the ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

However, it may cover Spravato, an FDA-approved drug deriving from ketamine, for treatment-resistant depression. Currently, the Food and Drug Administration (FDA) only approves ketamine for use as ...

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

According to reports, the FDA approved the Johnson & Johnson drug called Spravato (esketamine) to treat some cases of depression in the 2019 however, this was only allowed as a prescription ...

The New York Mets are setting high expectations for one of their brightest young stars entering 2025. Luisangel Acuña will be stepping into a larger role this season, despite not being projected to ...